• Test Code:
  • Department:
  • Test Synonyms:
    HypoalphalipoproteinemiaCholesteryl ester Transferase DeficiencyCETP deficiency
  • CPT Code(s):
    Contact KDL for billing information

Lipid disorders comprise a group of heterogenic conditions often with overlapping clinical features such as abnormal levels of HDL, LDL, or triglycerides. High levels of HDL cholesterol in blood have been shown to atherogenic; these conditions include hypoalphalipoproteinemia and cholesteryl ester transferase deficiency.  This next-generation sequencing test is designed to detect mutations in the coding region of 3 genes associated with high HDL levels.

Reasons for Referral:

  • Abnormally high levels of HDL cholesterol.
  • Clinical presentation consistent with a lipid disorder.
  • Positive family history for High HDL (targeted testing is available if familial mutation is known).
  • Carrier testing.
For detailed information and ordering instructions, please refer to Full Gene Analysis (1240). Genes may be added or removed from the list below if clinically indicated.

High HDL Panel (3 genes):



Specimen Requirements:

Test Performed (Days):

Turn Around Time:

Shipment Sensitivity Requirements:


Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More